Dulaglutide vs FGL
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Dulaglutide
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist for type 2 diabetes. Its larger molecular size from fusion with an Fc fragment extends half-life and may reduce some GI side effects.
Full details →FGL
FGL (FG Loop) is a synthetic peptide that mimics the neural cell adhesion molecule (NCAM) FG loop region. It promotes neuroplasticity and has shown cognitive-enhancing effects in research.
Full details →Side-by-Side Comparison
| Aspect | Dulaglutide | FGL |
|---|---|---|
| Mechanism | GLP-1 analog fused to a modified human IgG4 Fc fragment, providing extended duration of action. Activates GLP-1 receptors for glucose-dependent insulin secretion and appetite suppression. | Binds to FGFR1 (fibroblast growth factor receptor 1) to activate downstream signaling cascades that promote neurite outgrowth, synaptic plasticity, and neuronal survival. |
| Typical Dosage | Start at 0.75mg once weekly, may increase to 1.5mg, 3mg, or maximum 4.5mg weekly based on glycemic response. | Research protocols have used subcutaneous doses ranging from 1-10mg. Intranasal administration also studied. Optimal dosing not established. |
| Administration | Subcutaneous injection once weekly, any time of day, with or without food. Comes in pre-filled single-dose pens. | Subcutaneous injection or intranasal administration. Research compound with limited human dosing data. |
| Side Effects | Nausea, diarrhea, vomiting, abdominal pain, decreased appetite. Generally well-tolerated with gradual dose titration. | Limited human data available. Animal studies show good tolerability. |
| Best For |